A recent study published in the New England Journal of Medicine examined the pricing practices of hospitals participating in the 340B drug discount program, revealing significant markups on doctor-administered infusion drugs compared to independent practices and non-340B hospitals.
Utilizing claims data from Blue Cross Blue Shield spanning 2020-2021, the research found significant disparities in price markups. Specifically, markups for some commonly administered infusion drugs were 6.59 times higher at 340B hospitals than at independent doctor practices, and 4.34 times higher than at non-340B hospitals. These findings underscore concerns regarding the program’s potential for incentivizing hospitals to prioritize revenue over patient access to care.
Read the study here.
Last Updated on February 8, 2024 by Aimed Alliance
